Deal Diligence #006 — Medical Device Distribution at 6.07x SDE on a 62.5% Margin

Preheader: Deep dive on the highest-margin listing in Issue 007. A medical device distribution business in upstate New York asking $9.5M against $1.564M SDE on $2.5M revenue. Why a 62.5% margin in this category is mathematically achievable only through founder labor inclusion and aggressive add-back treatment, what normalization produces, what "exclusive territory" actually means as an asset, and why the SBA-range buyer is not the right buyer for this listing regardless of how the multiple is read.

A medical device distribution business based in Onondaga County, New York came to market this week at $9,499,999 asking on $1,564,211 trailing SDE. The implied multiple is 6.07x SDE, the highest valid-sample multiple in Issue 007 and 27% above the week's sample median of 4.78x. The reported revenue is $2,502,895, producing an SDE margin of 62.5%.

The headline numbers, as disclosed:

The listing sits inside the Healthcare systematized sub-segment introduced in Issue 006 and expanded in Issue 007. The cumulative Healthcare systematized median across four observations is 6.24x. The 6.07x asking is approximately at that median, which is the surface-level reading: this is a systematized Healthcare business priced at the systematized Healthcare median, and there is nothing remarkable about the multiple itself.

The surface-level reading is wrong. The 62.5% SDE margin is the diligence trigger, not the multiple. A medical device distribution business cannot produce a 62.5% SDE margin under any normal operating model. The reported number is the founder's economic accounting of the business, not the business's economic accounting of itself. Once normalized, the deal looks different in three ways: the implied multiple rises to 8-12x, the asking price still appears defensible, and the buyer pool changes from SBA-range acquirers to medical device specialty PE and strategic platforms. The remainder of this Deep Dive develops each of these.

B2B distribution businesses operate at structurally constrained margins because the model intermediates between manufacturer and end-user without owning the underlying product economics. A distributor purchases inventory or assumes commission rights, applies a markup or commission percentage, and earns the spread. The cost structure includes inventory carrying costs (or commission-shared infrastructure), sales force expense, customer relationship management, and any required certifications or compliance overhead. Industry data places typical B2B distribution SDE margins in the 15-25% range, with specialty subcategories occasionally reaching 30-35% when the distributor controls a regulated or technically complex product line.

Medical device distribution sits at the upper end of B2B distribution category economics for specific reasons. Devices in regulated classes (FDA Class II or III) require representative training, customer-facing technical expertise, and sometimes hospital credentialing for procedure-room presence. These barriers support higher margins than commodity distribution. But the upper bound of normal operating economics for an SBA-range medical device distribution business sits in the 30-35% range, not the 62.5% the listing reports.

The 62.5% figure exceeds the upper bound of the category's normal operating margins by approximately 32 percentage points. The arithmetic gap is the diligence question. There are five reconciling hypotheses, all of which are testable in diligence:

The first is founder labor inclusion. SDE by definition adds back the owner's reasonable compensation. A founder who personally performs the sales function (the relationship-managed account coverage, the hospital and physician interaction, the territory representation) accumulates substantial labor value that flows to SDE rather than to wage expense. Medical device sales representatives in specialty territories earn $150K-$400K in total compensation depending on category and tenure. If the founder is performing 1.0-1.5 FTE of sales representation labor, $300K-$600K of founder labor is being captured as SDE rather than expensed.

The second is aggressive add-back treatment. Distribution businesses with W-2 family members on the payroll, vehicle leases for personal use, owner health insurance, professional services attributable to the owner's personal interests, and similar items often add these back to compute SDE. The cumulative effect on a $2.5M revenue business can be $100K-$300K in additional add-backs above the founder labor figure.

The third is drop-ship or commission-only operating model. A distribution business that never holds inventory (manufacturer ships direct to end-user, distributor earns commission on the transaction) carries materially less cost than a business that buys, warehouses, and resells. Commission-only medical device representation can produce 40-50% operating margins because there is no cost of goods sold flowing through the distributor's P&L. The distributor's revenue is the commission, not the gross device sale.

The fourth is exclusive territory pricing power. A genuinely exclusive territory with multi-year contractual protection and minimum-volume guarantees from the manufacturer can support a premium margin because the distributor's revenue is contractually protected from competition. This is the strongest legitimate explanation for an elevated margin in this category, and the listing's "exclusive territory" descriptor makes it the explanation the buyer must verify first.

The fifth is revenue recognition timing. A business operating on cash basis rather than accrual can report SDE that does not match the underlying economic activity of the same period, particularly when contracts include performance bonuses or year-end true-ups paid in cash but earned across multiple periods.

The buyer's diligence task is to determine which combination of these five explanations produces the reported figures, and which of the explanations are durable post-transition versus extinguished at closing.

The normalization math is direct. Assume the founder personally performs 1.0 FTE of sales territory representation at market compensation for the role. Specialty medical device sales representatives in established territories earn $250K-$400K in cash compensation plus 10-25% in benefits and employer overhead, producing a fully-loaded annual cost of $300K-$500K. Subtracting a midpoint $400K from the reported $1.564M SDE produces a normalized SDE of $1.164M, a normalized margin of 46.5%, and an implied multiple at the $9.5M asking price of 8.16x.

If the founder labor is closer to 1.5 FTE (which is common in owner-operator distribution businesses where the founder handles sales plus general management plus some customer service), the replacement cost is $500K-$700K. At the higher midpoint $600K, normalized SDE is $964K, normalized margin is 38.5%, and the implied multiple is 9.85x.

If add-back recovery on top of founder labor adds another $100K-$200K of expense the buyer must absorb post-close, the normalized multiple moves to 10.5x-12.5x.

The range of normalized multiples (8.16x at the low end of normalization, 12.4x at the higher end) is informative for two reasons. First, the lower end of the range (8-9x) sits within the medical device specialty buyer pool's typical pricing band of 8-12x EBITDA for sub-$5M EBITDA targets. The asking price is defensible at the lower end of normalization. Second, the higher end of the range (11-12x) is at the top of the specialty buyer pool's range and would require strategic synergy or specific category positioning to justify.

The buyer's analytical task is to determine where in this range the normalized economics actually sit. This is documentable through the tax return reconciliation (which identifies actual founder compensation), the add-back schedule (which identifies every item flowing from book earnings to reported SDE), the sales force cost benchmarking (which establishes what the founder's replacement actually costs), and the operating cost trajectory under historical ownership (which reveals whether costs have been minimized in preparation for sale).

The directional conclusion is consistent across the range: the reported 62.5% margin is not the business's actual operating margin, the actual operating margin is closer to 30-45% depending on normalization severity, and the asking price is defensible at the normalized economics but only at the upper boundary of the appropriate buyer pool. The 6.07x headline multiple understates the economic reality. The deal is more expensive than it looks once labor is properly attributed.

The listing's framing as an "exclusive territory" distribution business is the second variable that determines whether the asking price is defensible. The term covers several different commercial arrangements with materially different transfer characteristics.

A manufacturer's representative agreement gives the distributor exclusive right to represent the manufacturer's products in a defined geographic territory, typically for a defined term, with renewal contingent on performance metrics (quota achievement, customer satisfaction, market development activities). These agreements are generally personal in nature, meaning the manufacturer's consent is required for transfer to a new owner. The agreement value to the buyer depends on the transfer terms, the remaining term length at closing, the renewal mechanics, and the manufacturer's relationship with the founder versus the institutional relationship with the business.

A distributor agreement is structurally similar but typically involves the distributor purchasing inventory from the manufacturer at a wholesale price and reselling to end-users at a marked-up price, rather than earning a commission on the manufacturer's sale. The buyer assumes inventory risk and working capital exposure that a commission-only manufacturer's representative does not carry. Transfer mechanics are similar (manufacturer consent required), but the working capital implications for the new owner are larger.

A specialty product distribution license can grant exclusive rights to distribute a particular regulated product (a drug device, a Class III implantable, a diagnostic system) within a territory. These arrangements are most valuable when the underlying product has clinical adoption barriers that the founder has overcome through years of physician relationship development. The buyer's value in such cases comes partly from the territory exclusivity and partly from the inherited customer relationships, and the two are not separable. A buyer who cannot maintain the customer relationships does not capture the full value of the exclusivity.

The diligence question for each of these arrangements is identical: what specifically is being conveyed at closing, on what terms, with what transferability protection, and what happens if the manufacturer or the underlying product relationship terminates. The listing's "exclusive territory" descriptor is a label. The underlying contract is the asset. A buyer who pays for the exclusivity without verifying the contract is paying for the description rather than the substance.

A specific concern in this category: medical device manufacturers periodically restructure their distribution channels (consolidating territories, shifting from independent representatives to direct sales force, replacing distributor models with manufacturer-employee coverage). These channel decisions are made unilaterally by the manufacturer and can extinguish a distributor's revenue base on a notice period of 60-180 days regardless of the contract's stated term, depending on the contract's termination provisions. The buyer must read the actual termination clause, not the marketing description of the exclusivity.

The normalized economics determine the buyer pool. At a defended price of $9.5M against $1.0-$1.2M of fully-normalized SDE, the implied multiple is 8-9x SDE. This pricing band sits inside the medical device specialty buyer pool's typical range but outside the conventional SBA-range buyer pool's capacity.

The medical device specialty buyer pool in 2026 consists of category-focused private equity platforms (Linden Capital Partners, Patient Square Capital, Audax Group, Riverside Company, Frazier Healthcare Partners), Tier 1 medical contract manufacturer strategics expanding into adjacent distribution capability, regional consolidators building out geographic coverage in specific device categories, and search funders or family offices with prior medical device experience and the capital base to deploy at this scale. Industry M&A data places this buyer pool's pricing band at 8-12x EBITDA for sub-$5M EBITDA targets in specialty categories, with the higher end of the range reserved for businesses with proprietary positioning or platform-scaling potential.

The SBA-range buyer pool faces three structural constraints on this listing. The first is loan capacity. SBA 7(a) loan limits cap most transactions at $5M, with structured deals occasionally reaching $7-8M with seller financing and equity participation. A $9.5M asking against normalized SDE that requires lender comfort with the normalization is unlikely to clear conventional SBA underwriting. The second is category expertise. Medical device distribution requires understanding of FDA regulatory classifications, GPO and IDN relationships, physician credentialing pathways, and Stark Law / Anti-Kickback Statute compliance. Generalist SBA-range acquirers without this expertise face execution risk that lenders price into financing terms. The third is the transition complexity. The exclusive territory's value depends on manufacturer consent to transfer and continued performance under the agreement's renewal mechanics. A buyer without category experience may struggle to obtain manufacturer consent or to perform at quota levels required for renewal.

The implication for the listing's seller and broker: marketing the deal to SBA-range buyers is unlikely to produce a transaction at the asking price. The buyer pool that can underwrite this deal at $9.5M is the specialty medical device buyer pool, and that pool's diligence process is materially more rigorous than typical SBA-range diligence. The 62.5% headline margin that may attract SBA-range interest will be normalized aggressively by specialty PE diligence, and the conversation moves from "is this a good business" to "is this a good business at this price for our platform."

For the SBA-range buyer who encounters this listing through a general SMB acquisition search: the right read is that the listing is not in the right buyer pool. Pursuing it requires either accepting category execution risk that exceeds typical SBA-range deals, structuring with substantially more equity and seller participation than standard SBA financing supports, or partnering with a category-specific operator who carries the relationships and regulatory expertise the listing's value depends on.

Deal Diligence #003 analyzed an Arizona Med Spa at 8.33x SDE on a 38% margin. The verdict was that the 8.33x multiple was the seller's framing rather than category-representative pricing, and that normalization moved the multiple closer to category norms for practitioner-dependent clinical practices. The seller's price did not survive normalization in that analysis.

This listing is not the same anomaly. The margin claim is more extreme (62.5% versus 38%), but the asking price is potentially defensible at the normalized economics rather than indefensible. The difference is the category and the buyer pool. A practitioner-dependent Med Spa at 38% margin normalizes downward because the buyer pool (other physician operators, regional clinic platforms) does not pay for practitioner-attributed earnings at the same multiple as transferable earnings. A medical device distribution business at 62.5% margin normalizes downward, but the normalized economics still support the asking price because the appropriate buyer pool (medical device specialty PE) pays 8-12x for the normalized earnings.

The structural difference is that systematized businesses in regulated categories can support higher multiples than practitioner-dependent businesses, even after normalization, because the systematization itself transfers. A medical device distribution business with a documented exclusive territory and transferable customer relationships is selling a system; the founder's labor is recoverable through hiring, and the manufacturer relationship and customer base remain with the entity. The Med Spa's premium was not transferable. The Medical Device Distribution premium is transferable, contingent on the contract transfer and the customer relationship retention.

The Issue 007 Healthcare sub-segmentation framework holds in both cases, but the diligence implications differ. Practitioner-dependent listings warrant skepticism of headline multiples because the underlying earnings do not transfer. Systematized listings warrant skepticism of headline margins because the headline frequently includes founder labor that does transfer to a replacement, but the multiple after normalization can still be in the right range for the appropriate buyer pool.

Documents that determine whether the normalized economics support the asking price:

Three years of P&L on accrual basis with the full add-back schedule itemized, the founder's actual W-2 compensation and any 1099 income received from the business, the cost-of-goods structure for any owned inventory, and the commission income breakdown for any commission-based revenue streams. Reconciliation between accrual-basis financials and the trailing SDE figure represented in the listing.

Replacement-labor benchmarking for the founder's specific functional roles. Sales representation, account management, customer service, regulatory compliance, financial management. The benchmark cost for replacing each function at market rates determines the normalization adjustment.

Documents that determine whether the exclusive territory is transferable:

The complete manufacturer or distributor agreement with all amendments, addenda, and side letters. Specific attention to the term length, the remaining term at the projected closing date, the termination provisions (including for convenience, for cause, for change of control, and for performance), the renewal mechanics, and any minimum volume or performance requirements.

A written confirmation from the manufacturer or the principal counterparty regarding their position on transfer of the agreement to the buyer. Letter or email correspondence dated within the last 60 days. Verbal assurances from the seller are not sufficient; the manufacturer's position is the determinative variable.

The customer concentration analysis. Top-10 customer revenue by year for the trailing 3 years, with stated reasons for any customer transitions in or out of the top-10 list. Customer relationship attribution (which customers are tied to the founder personally versus the institutional business).

Documents that determine the regulatory and compliance posture:

The FDA classification of the products distributed, the regulatory pathway under which each product is marketed, and any open or recent regulatory communications regarding the products or the distribution channel.

Compliance with Stark Law and Anti-Kickback Statute (AKS) where applicable, particularly if any customers are physician-owned or physician-influenced. AKS exposure is the single largest hidden liability category in medical device distribution and is not visible on the cover sheet.

GPO contract status if applicable, including pricing tier and contract renewal timeline. GPO contracts are critical revenue protection in this category and their loss can compress revenue by 30-50% within a contract cycle.

The Medical Device Distribution listing at $9.5M / 6.07x SDE is not mispriced relative to its category once normalization is applied. The 62.5% headline margin overstates the true operating economics by approximately 25-30 percentage points, and the normalized multiple at 8-12x sits inside the medical device specialty buyer pool's typical pricing band. The asking price is defensible, but only at the upper boundary of the appropriate buyer pool's range, which means execution requires the right buyer and a substantially more rigorous diligence process than the headline numbers suggest.

Two buyer profiles can underwrite this listing at the asking price. A medical device specialty PE platform with adjacent or overlapping category coverage, treating the acquisition as a bolt-on with operational integration and management infrastructure already in place. A strategic acquirer (a Tier 1 medical device contract manufacturer expanding into distribution, or a regional consolidator building geographic coverage in the relevant device subcategory) where the customer relationships and exclusive territory contribute to a broader platform strategy.

Three buyer profiles should not engage. An SBA-financed individual buyer without category experience, because the financing capacity, the diligence rigor, and the operational continuity required exceed typical SBA-range execution. A generalist search funder pursuing this as a single-asset acquisition without category-specific operator support, because the manufacturer consent process and the customer relationship transition exceed first-time-buyer execution capability. A buyer attracted specifically by the 62.5% reported margin, because that buyer is purchasing the headline rather than the substance and will not survive the normalization conversation with specialty PE diligence.

A structured deal that fits the analysis: $6.5-7.5M cash at close against normalized SDE (founder labor replaced, add-backs recovered), with an earnout up to $2.5-3.0M tied to specific milestones including manufacturer consent confirmation within 60 days of closing, customer retention at named revenue thresholds through the first 12-18 months, and renewal of the exclusive territory agreement at terms no worse than the trailing agreement. The seller continues in a transition role for 6-12 months to manage manufacturer relationship handoff and key customer introductions, with non-compete and non-solicitation provisions enforced at full geographic and temporal scope. This structure prices the verifiable economics at close and reserves the contingent value (manufacturer continuity, customer retention) for performance through the transition.

The broader lesson, applicable beyond this deal: a reported margin substantially above category norms in a systematized business is not the same anomaly as a reported margin substantially above category norms in a practitioner-dependent business. Both warrant normalization, but the conclusion after normalization differs. Practitioner-dependent margins frequently do not survive normalization because the labor is not separable from the earnings. Systematized margins frequently do survive normalization because the labor is replaceable, and the question becomes whether the asking price still fits the appropriate buyer pool after the replacement cost is properly attributed. A buyer who treats the systematized-but-margin-inflated case as the same problem as the practitioner-dependent case will misprice the deal in one direction; a buyer who treats it as if the headline margin were real will misprice the deal in the other.

The right read is neither. The reported margin is a starting point that must be normalized. The normalized economics determine the appropriate buyer pool. The buyer pool determines the realistic clearing price. For this listing, the chain produces a defended asking price that an SBA-range buyer cannot pursue and a specialty buyer can. The headline 6.07x multiple is misleading in both directions, and the work of this Deep Dive has been to identify what the corrected reading actually is.

Deal Diligence is published Sundays. Issue 008 of the weekly market scan publishes Tuesday, June 2.

Not legal, financial, or investment advice. Independent verification and professional diligence required before any acquisition decision.